Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Earnings for Talaris Therapeutics, Inc. (TALS)
Earnings in 2022 (TTM): $-73,894,000
According to Talaris Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-73,894,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Talaris Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-73,894,000 | $-68,728,000 |
| 2021 | $-47,833,000 | $-48,159,000 |
| 2020 | $-22,707,000 | $-22,730,000 |
| 2019 | $-18,155,000 | $-17,932,000 |